What is Rigel Pharmaceuticals's market cap?

Rigel Pharmaceuticals (RIGL) has a market capitalization of $691.8M and trades on NASDAQ.

What is Rigel Pharmaceuticals's revenue and profitability?

Rigel Pharmaceuticals generated $299.8M in trailing twelve-month revenue with net income of $364.2M, representing a net margin of 121.5%. Gross margin stands at 93.4%. These figures are based on the Q1 2026 filing.

Who are Rigel Pharmaceuticals's competitors?

Rigel Pharmaceuticals's key competitors include Agios Pharmaceuticals, Amgen, Rezolute, Inc. Common Stock (NV), and others. These companies compete in similar markets and product categories.

Who does Rigel Pharmaceuticals partner with?

Rigel Pharmaceuticals's notable partners include Eli Lilly and Company, Novo Nordisk, Sanofi SA, and others.

Where is Rigel Pharmaceuticals headquartered?

Rigel Pharmaceuticals is headquartered in United States of America and employs approximately 147 people. It has been publicly traded since 2000.

Rigel Pharmaceuticals

RIGL

Rigel Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of novel small molecule therapies for hematologic disorders and cancer.

Market cap

$691.79M+84.2%

Revenue$299.8M+47.6%

Net income$364.2M+880%

EPS (diluted)$19.28+827%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$58.8MMiss by $3.6M EPS$0.44Miss by $0.30

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$55.3M

EPS estimate$0.13

Financials

Q1 2026

Income statement

See full

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

See full

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

See full

Operating cash flow$2.7M+405%

Valuation & ratios

Valuation

See full

Market cap$691.79M+84.2%

Enterprise value$735.69M+141%

P/E1.9×-1.8×

P/S2.3×+1.0×

Profitability

See full

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

Returns & leverage

See full

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Segments

By product

See full

Gross product sales$75.4M+25.2%

Delivery of drug supplies, royalties and others$3.9M-42.6%

Development Milestones--100%

Discounts and allowances-$20.5M-23.0%

By segment

See full

Single reportable segment$58.8M—

Competitors

By market cap

Amgen$203.07B+25.3%

Neurocrine Biosciences$17.7B+34.0%

Mirum Pharmaceuticals, Inc.$7.0B+173%

Agios Pharmaceuticals$2.2B+2.1%

Rigel Pharmaceuticals$691.8M+93.6%

Zevra Therapeutics, Inc.$574.0M-2.9%

Rezolute$475.7M-14.3%

Vanda Pharmaceuticals$313.9M+13.3%

By revenue growth

Zevra Therapeutics, Inc.+201%

Agios Pharmaceuticals+78.3%

Mirum Pharmaceuticals, Inc.+50.2%

Rigel Pharmaceuticals+47.6%

Neurocrine Biosciences+28.6%

Amgen+9.1%

By net margin

Rigel Pharmaceuticals121.51%+103pp

Zevra Therapeutics, Inc.101.58%+328pp

Neurocrine Biosciences21.55%+8.9pp

Amgen20.96%+3.6pp

Mirum Pharmaceuticals, Inc.-140.24%-120pp

Agios Pharmaceuticals-639.84%-2,479pp

Profile

Rigel Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of novel small molecule therapies for hematologic disorders and cancer. The company targets specific signaling pathways, such as SYK, IDH1, and RET, to address critical disease mechanisms in patients with limited treatment options.

Competitive position

A commercial-stage biotech with a leading position in oral SYK inhibition for ITP and a growing portfolio in targeted oncology.

GeographiesUnited States, Europe, United Kingdom, Japan, South Korea, Canada, Israel

Customer segmentsPatients, Healthcare Providers

Business modelProduct-based, Licensing, R&D

SuppliersContract Manufacturing Organizations, Clinical Research Organizations, In-licensing partners

CustomersSpecialty Distributors, Wholesalers, Healthcare Systems

CountryUnited States of America

Listed2000

Employees147.0

CEORaul R. Rodriguez

SectorHealthcare

IndustryBiotechnology

Websiterigel.com

FilingsSEC EDGAR

Ask your AI about Rigel Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rigel Pharmaceuticals's market cap?: Rigel Pharmaceuticals (RIGL) has a market capitalization of $691.8M and trades on NASDAQ.
What is Rigel Pharmaceuticals's revenue and profitability?: Rigel Pharmaceuticals generated $299.8M in trailing twelve-month revenue with net income of $364.2M, representing a net margin of 121.5%. Gross margin stands at 93.4%. These figures are based on the Q1 2026 filing.
Who are Rigel Pharmaceuticals's competitors?: Rigel Pharmaceuticals's key competitors include Agios Pharmaceuticals, Amgen, Rezolute, Inc. Common Stock (NV), and others. These companies compete in similar markets and product categories.
Who does Rigel Pharmaceuticals partner with?: Rigel Pharmaceuticals's notable partners include Eli Lilly and Company, Novo Nordisk, Sanofi SA, and others.
Where is Rigel Pharmaceuticals headquartered?: Rigel Pharmaceuticals is headquartered in United States of America and employs approximately 147 people. It has been publicly traded since 2000.